EUDA Health (EUDA) announced that it has entered into an amendment to its previously disclosed warrant agreement with Streeterville Capital. On December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant from $6.00 per share to $4.00 per share and (ii) reduce the minimum closing price required to trigger a “Forced Exercise” from $7.50 to $6.00. All other terms of the warrant remain unchanged.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
- EUDA Health Launches Nationwide Stem Cell and Cryostorage Platform in China
- EUDA launches stem cell extraction, cryostorage, clinical delivery platform
- EUDA Health to Launch Helixé 2.0 Longevity Supplement with Halal Certification in January 2026
- EUDA Health to launch EUDA Helixe 2.0 in January
- EUDA Health Launches Stem Cell Platform and First Longevity Clinic in Shenzhen